Application 202211
- Type
- NDA
- Sponsor
- ALLERGAN
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | OXYTROL FOR WOMEN | OXYBUTYNIN | FILM, EXTENDED RELEASE;TRANSDERMAL | 3.9MG/24HR | Yes | Yes |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N202211-001 | OXYTROL FOR WOMEN | OXYBUTYNIN | 3.9MG/24HR | FILM, EXTENDED RELEASE / TRANSDERMAL | RLD, RS | 2013-01-25 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N202211-001 | OXYTROL FOR WOMEN | 3.9MG/24HR | FILM, EXTENDED RELEASE / TRANSDERMAL | RLD, RS | 2013-01-25 | 3a93d1ddd44b… | |
| 2022-10-28 04:53 UTC | 2022-10 | N202211-001 | OXYTROL FOR WOMEN | 3.9MG/24HR | FILM, EXTENDED RELEASE / TRANSDERMAL | RLD, RS | 2013-01-25 | f41ea6bd6efb… | |
| 2022-09-29 23:25 UTC | 2022-09 | N202211-001 | OXYTROL FOR WOMEN | 3.9MG/24HR | FILM, EXTENDED RELEASE / TRANSDERMAL | RLD, RS | 2013-01-25 | e64feba35796… | |
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | N202211-001 | OXYTROL FOR WOMEN | 3.9MG/24HR | FILM, EXTENDED RELEASE / TRANSDERMAL | RLD, RS | 2013-01-25 | cb3db0bc1861… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N202211-001 | OXYTROL FOR WOMEN | 3.9MG/24HR | FILM, EXTENDED RELEASE / TRANSDERMAL | RLD, RS | 2013-01-25 | a50c72e98297… |
Observed Orange Book patent history#
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2019-12-13 00:20 UTC | 2019-12 | N202211-001 | 6743441 | 2020-04-26 | U-1329 | Drug product | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N202211-001 | 7081249 | 2020-04-26 | U-1329 | Drug product | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N202211-001 | 7081250 | 2020-04-26 | U-1329 | Drug product | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N202211-001 | 7081251 | 2020-04-26 | U-1329 | Drug product | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N202211-001 | 7081252 | 2020-04-26 | U-1329 | Drug product | 74a2ff9319b5… | |
| 2019-12-13 00:20 UTC | 2019-12 | N202211-001 | 7179483 | 2020-04-26 | U-1329 | 74a2ff9319b5… | ||
| 2020-12-22 03:56 UTC | 2020-12 | N202211-001 | 6743441 | 2020-04-26 | U-1329 | Drug product | 8869cabd3fbd… | |
| 2020-12-22 03:56 UTC | 2020-12 | N202211-001 | 7081249 | 2020-04-26 | U-1329 | Drug product | 8869cabd3fbd… | |
| 2020-12-22 03:56 UTC | 2020-12 | N202211-001 | 7081250 | 2020-04-26 | U-1329 | Drug product | 8869cabd3fbd… | |
| 2020-12-22 03:56 UTC | 2020-12 | N202211-001 | 7081251 | 2020-04-26 | U-1329 | Drug product | 8869cabd3fbd… | |
| 2020-12-22 03:56 UTC | 2020-12 | N202211-001 | 7081252 | 2020-04-26 | U-1329 | Drug product | 8869cabd3fbd… | |
| 2020-12-22 03:56 UTC | 2020-12 | N202211-001 | 7179483 | 2020-04-26 | U-1329 | 8869cabd3fbd… | ||
| 2020-11-12 02:37 UTC | 2020-11 | N202211-001 | 6743441 | 2020-04-26 | U-1329 | Drug product | c0c555d07b60… | |
| 2020-11-12 02:37 UTC | 2020-11 | N202211-001 | 7081249 | 2020-04-26 | U-1329 | Drug product | c0c555d07b60… | |
| 2020-11-12 02:37 UTC | 2020-11 | N202211-001 | 7081250 | 2020-04-26 | U-1329 | Drug product | c0c555d07b60… | |
| 2020-11-12 02:37 UTC | 2020-11 | N202211-001 | 7081251 | 2020-04-26 | U-1329 | Drug product | c0c555d07b60… | |
| 2020-11-12 02:37 UTC | 2020-11 | N202211-001 | 7081252 | 2020-04-26 | U-1329 | Drug product | c0c555d07b60… | |
| 2020-11-12 02:37 UTC | 2020-11 | N202211-001 | 7179483 | 2020-04-26 | U-1329 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | N202211-001 | 6743441 | 2020-04-26 | U-1329 | Drug product | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N202211-001 | 7081249 | 2020-04-26 | U-1329 | Drug product | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N202211-001 | 7081250 | 2020-04-26 | U-1329 | Drug product | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N202211-001 | 7081251 | 2020-04-26 | U-1329 | Drug product | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N202211-001 | 7081252 | 2020-04-26 | U-1329 | Drug product | 3f01610625f2… | |
| 2019-12-14 00:12 UTC | 2019-12 | N202211-001 | 7179483 | 2020-04-26 | U-1329 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | N202211-001 | 6743441 | 2020-04-26 | U-1329 | Drug product | b00525d2431f… | |
| 2019-09-15 20:21 UTC | 2019-09 | N202211-001 | 7081249 | 2020-04-26 | U-1329 | Drug product | b00525d2431f… | |
| 2019-09-15 20:21 UTC | 2019-09 | N202211-001 | 7081250 | 2020-04-26 | U-1329 | Drug product | b00525d2431f… | |
| 2019-09-15 20:21 UTC | 2019-09 | N202211-001 | 7081251 | 2020-04-26 | U-1329 | Drug product | b00525d2431f… | |
| 2019-09-15 20:21 UTC | 2019-09 | N202211-001 | 7081252 | 2020-04-26 | U-1329 | Drug product | b00525d2431f… | |
| 2019-09-15 20:21 UTC | 2019-09 | N202211-001 | 7179483 | 2020-04-26 | U-1329 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | N202211-001 | 6743441 | 2020-04-26 | U-1329 | Drug product | ea99ee380514… | |
| 2019-07-19 19:46 UTC | 2019-07 | N202211-001 | 7081249 | 2020-04-26 | U-1329 | Drug product | ea99ee380514… | |
| 2019-07-19 19:46 UTC | 2019-07 | N202211-001 | 7081250 | 2020-04-26 | U-1329 | Drug product | ea99ee380514… | |
| 2019-07-19 19:46 UTC | 2019-07 | N202211-001 | 7081251 | 2020-04-26 | U-1329 | Drug product | ea99ee380514… | |
| 2019-07-19 19:46 UTC | 2019-07 | N202211-001 | 7081252 | 2020-04-26 | U-1329 | Drug product | ea99ee380514… | |
| 2019-07-19 19:46 UTC | 2019-07 | N202211-001 | 7179483 | 2020-04-26 | U-1329 | ea99ee380514… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Oxytrol for Women | OXYBUTYNIN | Allergan, Inc. | 8cdc5b4d-ff8d-4010-97d7-313422a0b868 | 2024-08-15 | Warnings | 202211 NDA202211 0023-9637 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 0023-9637 | Oxytrol for Women | Oxybutynin | Allergan, Inc. | NDA | Current |
| 0023-9637 | Oxytrol for Women | Oxybutynin | Allergan, Inc. | NDA | Current |
| 0023-9637 | Oxytrol for Women | Oxybutynin | Allergan, Inc. | NDA | Current |
| 0023-9637 | Oxytrol for Women | Oxybutynin | Allergan, Inc. | NDA | Current |
| 52544-166 | Oxytrol For Women | oxybutynin | Actavis Pharma, Inc. | NDA | Current |